Philadelphia based Emvena Therapeutics announced an investment from the Penn BioNTech Innovative Therapeutics Seed Fund on 4 November 2026. The amount was explicitly not disclosed. Emvena is developing mRNA medicines for serious maternal and fetal health conditions, beginning with preeclampsia. The investment is the first made by the fund, which was established by the University of Pennsylvania and BioNTech to support therapeutic research originating from Penn. Emvena plans to advance its lead programme and generate the preclinical evidence required for further development. The financing combines academic science with specialist capital for a condition with limited treatment options.
Emvena receives undisclosed seed investment
Penn BioNTech fund backs maternal health mRNA research

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


